The aim of the present study is to assess multimodality imaging findings according to systemic biomarkers, high-sensitivity troponin I (hsTnI) and B-type natriuretic peptide (BNP) levels, in low-flow, low-gradient aortic stenosis (LFLG-AS). Elevated levels of BNP and hsTnI have been related with poor prognosis in patients with LFLG-AS. Prospective study with LFLG-AS patients that underwent hsTnI, BNP, coronary angiography, cardiac magnetic resonance (CMR) with T1 mapping, echocardiogram and dobutamine stress echocardiogram. Patients were divided into 3 groups according to BNP and hsTnI levels: Group 1 (  = 17) when BNP and hsTnI levels were below median BNP < 1.98 fold upper reference limit (URL) and hsTnI < 1.8 fold URL; Group 2 (  = 14) when BNP or hsTnI were higher than median; and Group 3 (  = 18) when both hsTnI and BNP were higher than median. 49 patients included in 3 groups. Clinical characteristics (including risk scores) were similar among groups. Group 3 patients had lower valvuloarterial impedance (  = 0.03) and lower left ventricular ejection fraction (  = 0.02) by echocardiogram. CMR identified a progressive increase of right and left ventricular chamber from Group 1 to Group 3, and worsening of left ventricular ejection fraction (EF) (40 31-47 vs. 32 29-41 vs. 26 19-33%;  < 0.01) and right ventricular EF (62 53-69 vs. 51 35-63 vs. 30 24-46%;  < 0.01). Besides, there was a marked increase in myocardial fibrosis assessed by extracellular volume fraction (ECV) (28.4 24.8-30.7 vs. 28.2 26.9-34.5 vs. 31.8 28.9-35.5%;  = 0.03) and indexed ECV (iECV) (28.7 21.2-39.1 vs. 28.8 25.4-39.9 vs. 44.2 36.4-51.2 ml/m , respectively;  < 0.01) from Group 1 to Group 3. Higher levels of BNP and hsTnI in LFLG-AS patients are associated with worse multi-modality evidence of cardiac remodeling and fibrosis.